Company profile: Invirsa
1.1 - Company Overview
Company description
- Provider of therapeutics based on INV-102, a compound that enhances the body's response to DNA damage to improve cell stability, DNA repair, and innate immune response. Programs target ocular injuries (including sulfur mustard exposure) and infectious keratoconjunctivitis, with studies exploring treatment of acute viral lung infections and UV-induced skin injuries.
Products and services
- INV-102: A DNA-repair–promoting, immunomodulatory therapeutic that enhances cellular response to DNA damage, stabilizes ocular cells, and augments innate immunity for injury and infectious keratoconjunctivitis
- Infectious Keratoconjunctivitis Treatment: An ocular-targeted, DNA-repair–enhancing therapy expected to treat both viral and bacterial conjunctivitis, addressing significant unmet need by bolstering innate immune response and cell stability
- Ocular Injury Treatment: A sulfur-mustard–focused application of INV-102 that maintains ocular cellular stability and improves DNA repair following sulfur mustard gas exposure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Invirsa
Eiger BioPharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, including lonafarnib, an oral farnesyl-transferase inhibitor blocking Hepatitis Delta Virus replication; avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism; Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies; and an Expanded Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eiger BioPharmaceuticals company profile →
Atea Pharmaceuticals
HQ: United States
Website
- Description: Provider of next-generation oral antivirals for severe human viral infections, including bemnifosbuvir (AT-527), an oral direct-acting antiviral in Phase 3 for COVID-19 targeting the SARS-CoV-2 RNA polymerase; a bemnifosbuvir + ruzasvir combination in Phase 2 for HCV; and a proprietary purine nucleos(t)ide prodrug platform targeting viral RNA polymerase for mono- and combination regimens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atea Pharmaceuticals company profile →
Isconova
HQ: Sweden
Website
- Description: Provider of adjuvants and vaccines, developing and commercializing adjuvants for veterinary and human vaccines to enhance immune reactions with longer duration. Products include Matrix-M, inducing cell- and antibody-mediated immune responses for use in vaccines for humans and dogs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Isconova company profile →
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Selux Diagnostics
HQ: United States
Website
- Description: Provider of next-generation phenotyping solutions for rapid antimicrobial susceptibility testing (AST). Offers the Selux NGP System, proprietary 384-well panels delivering exact MICs across a wide range of antibiotics, the Selux Separator and Inoculator for automated sample preparation from positive blood cultures, and Selux Site Software to streamline workflow and deliver actionable AST results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selux Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Invirsa
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Invirsa
2.2 - Growth funds investing in similar companies to Invirsa
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Invirsa
4.2 - Public trading comparable groups for Invirsa
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →